This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Gilead Sciences (GILD) Gets a Buy from Bernstein

Tipranks - Tipranks - Thu Jun 11, 6:52AM CDT

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences, with a price target of $160.00. The company’s shares closed yesterday at $125.50.

Introducing TipRanks MCP for Agents

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 20.4% and an 86.27% success rate on recommended stocks.

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $160.11, a 27.58% upside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a $165.00 price target.

See the top stocks recommended by analysts >>

Based on Gilead Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.96 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $6.67 billion and had a net profit of $1.32 billion

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).